Exelixis
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1994-01-01
- Employees
- 1.3K
- Market Cap
- $7.3B
- Website
- http://www.exelixis.com
- Introduction
Exelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic. The company was founded by Stelios Papadopoulos on November 15, 1994, and is headquartered in Alameda, CA.
Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101)
- First Posted Date
- 2021-01-27
- Last Posted Date
- 2024-05-14
- Lead Sponsor
- Exelixis
- Target Recruit Count
- 52
- Registration Number
- NCT04726332
- Locations
- 🇺🇸
Exelixis Clinical Site #2, Dallas, Texas, United States
🇺🇸Exelixis Clinical Site #4, Atlanta, Georgia, United States
🇺🇸Exelixis Clinical Site #3, Boston, Massachusetts, United States
Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC
- Conditions
- Interventions
- First Posted Date
- 2020-06-24
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Exelixis
- Target Recruit Count
- 575
- Registration Number
- NCT04446117
- Locations
- 🇺🇸
Exelixis Clinical Site #6, Baltimore, Maryland, United States
🇺🇸Exelixis Clinical Site #18, Philadelphia, Pennsylvania, United States
🇵🇱Exelixis Clinical Site #243, Otwock, Mazowieckie, Poland
Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2019-05-03
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Exelixis
- Target Recruit Count
- 855
- Registration Number
- NCT03937219
- Locations
- 🇺🇸
Exelixis Clinical Site #29, Boca Raton, Florida, United States
🇺🇸Exelixis Clinical Site #58A, Baltimore, Maryland, United States
🇺🇸Exelixis Clinical Site #12, Pittsburgh, Pennsylvania, United States
A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2019-02-19
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Exelixis
- Target Recruit Count
- 325
- Registration Number
- NCT03845166
- Locations
- 🇺🇸
Exelixis Clinical Site #84, Los Angeles, California, United States
🇺🇸Exelixis Clinical Site #71, Stanford, California, United States
🇺🇸Exelixis Clinical Site #85, Bronx, New York, United States
Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Subjects With Advanced HCC Who Have Not Received Previous Systemic Anticancer Therapy
- Conditions
- Interventions
- First Posted Date
- 2018-11-28
- Last Posted Date
- 2024-03-22
- Lead Sponsor
- Exelixis
- Target Recruit Count
- 837
- Registration Number
- NCT03755791
- Locations
- 🇺🇸
Exelixis Clinical Site #88, Philadelphia, Pennsylvania, United States
🇦🇺Exelixis Clinical Site #78, Camperdown, New South Wales, Australia
🇺🇸Exelixis Clinical Site #7, Burlington, Massachusetts, United States
A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy
- Conditions
- Interventions
- First Posted Date
- 2018-10-01
- Last Posted Date
- 2024-03-22
- Lead Sponsor
- Exelixis
- Target Recruit Count
- 187
- Registration Number
- NCT03690388
- Locations
- 🇺🇸
Exelixis Clinical Site #2, Newport Beach, California, United States
🇺🇸Exelixis Clinical Site #153, Boston, Massachusetts, United States
🇺🇸Exelixis Clinical Site #75, Pittsburgh, Pennsylvania, United States
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2017-05-31
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Exelixis
- Target Recruit Count
- 1732
- Registration Number
- NCT03170960
- Locations
- 🇺🇸
Exelixis Clinical Site #51, Newport Beach, California, United States
🇪🇸Exelixis Clinical Site #94, Oviedo, Asturias, Spain
🇺🇸Exelixis Clinical Site #10, Boston, Massachusetts, United States
Study of Cabozantinib in Combination With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic Castration-Resistant Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-11-26
- Last Posted Date
- 2015-02-20
- Lead Sponsor
- Exelixis
- Target Recruit Count
- 54
- Registration Number
- NCT01995058
Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib
- Conditions
- Interventions
- First Posted Date
- 2013-07-25
- Last Posted Date
- 2021-05-06
- Lead Sponsor
- Exelixis
- Target Recruit Count
- 707
- Registration Number
- NCT01908426
A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-07-11
- Last Posted Date
- 2023-07-12
- Lead Sponsor
- Exelixis
- Target Recruit Count
- 247
- Registration Number
- NCT01896479